Notícias

West Pharmaceutical Services (NYSE:WST) has entered new long-term exclusive and non-exclusive distributorship agreements with Daikyo Seiko. West Pharmaceutical will distribute Daikyo products outside Japan, while Daikyo will distribute more West products within Japan. The agreements are structured to run over the next decade, reinforcing the companies' cross-border partnership in drug packaging technologies. West Pharmaceutical Services comes into this new distribution arrangement with...

A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HCA Healthcare's recent earnings report, which pointed to a 'negative payer mix shift.' This term refers to a change in the types of insurance patients have, in this case, an increase in uninsured individuals resulting from losses in health insurance exchange coverage. For HCA, this shift was significant, reducing pre-tax income by an estimated $400 million

COR's specialty expansion, supply-chain investments and international momentum support growth, though pricing, debt and regulation pose risks.

RVTY's T-SPOT A201 targets a 2027 launch, promising high-throughput latent TB testing with greater lab efficiency and scalability.

SOLV's innovation, cost savings and strong segment demand support growth, while raw material cost increases remain a key risk.

Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.

West Pharmaceutical Services (NYSE:WST) raised its full-year 2026 outlook after reporting second-quarter results that topped management’s expectations, supported by strong demand for high-value product components, biologics-related offerings and GLP-1 elastomers. Chief Executive Officer and Board C

Moby summary of West Pharmaceutical Services, Inc.'s Q2 2026 earnings call

West Pharmaceutical Services Inc (WST) reports robust Q2 results with significant revenue and EPS growth, while raising full-year guidance amidst global expansion and strategic initiatives.

WST tops Q2 earnings and revenue estimates, lifts its 2026 EPS outlook and sees shares surge as high-value products fuel strong growth.

QDEL's strong portfolio, cost-saving progress and mixed first-quarter results support growth, though respiratory reliance remains a risk.

SNN expands ASC Solutions with an integrated platform, analytics and partners to boost efficiency, growth and patient outcomes in outpatient care.

OPKO Health's growth outlook rests on RAYALDEE, BioReference gains and partnerships, though losses and pipeline risks persist.

CNMD's FDA-expanded AirSeal indication adds da Vinci 5 hex cannula compatibility, supporting broader use across Intuitive Surgical's robotic systems.

While the top- and bottom-line numbers for West Pharmaceutical (WST) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.

West Pharmaceutical (WST) delivered earnings and revenue surprises of +13.94% and +4.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

West Pharmaceutical Services (WST) reported Q2 adjusted earnings Thursday of $2.37 per diluted share

Healthcare products company West Pharmaceutical Services (NYSE:WST) will be announcing earnings results tomorrow before market open. Here’s what to expect.

CAH is set to buy two home-care businesses for about $360 million, expanding diabetes and urology reach while targeting first-year EPS accretion.

RVTY's Signals for Startups gives early-stage biotechs scalable software and guided onboarding to streamline research and support future growth.

West Pharmaceutical Services stock has delivered a 64.7% return over the past year, yet the valuation checks and current pricing suggest it may no longer be an obvious bargain, with the Discounted Cash Flow (DCF) estimate pointing to a level that is roughly in line with where the shares trade today. After such a strong run, investors are weighing solid business developments against signals that the stock screens as expensive on several measures. Over the past 1 year, West Pharmaceutical...

WST heads into Q2 earnings with expectations for revenue and EPS growth, backed by demand for biologics and GLP-1 components plus manufacturing gains.

OMCL heads into Q2 earnings with OmniSphere adoption, Connected Devices execution and recurring revenue growth ahead of July 30 results.

GE HealthCare's MIM Anyware offers secure browser-based imaging access to streamline workflows, collaboration and clinical decision-making.

Wall Street closed lower on Monday, pulled down by healthcare and industrial stocks.

Besides Wall Street's top-and-bottom-line estimates for West Pharmaceutical (WST), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.

MMSI vs. WST: Which Stock Is the Better Value Option?

ALGN reports Q2 results on July 29, with investors watching Clear Aligner growth as higher volumes and digital offerings shape quarterly performance.

BLCO launches EyeGility in the United States, pairing preloaded enVista Aspire lenses with smoother handling, one-handed use and surgical flexibility.